WAVE Life Sciences to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company
focused on developing stereopure nucleic acid therapies for patients
with rare diseases, today announced that Paul Bolno, M.D., MBA,
President and Chief Executive Officer, will participate in a fireside
chat and provide a company overview at the JMP Securities Life Sciences
Conference at 2:30 PM Eastern Time on Tuesday, June 21, 2016 in New
York, NY.
About WAVE Life Sciences
At WAVE Life Sciences, we are driven by an unwavering passion and
commitment to deliver on our mission of confronting challenging diseases
by developing transformational therapies and empowering patients. We are
utilizing our innovative and proprietary synthetic chemistry drug
development platform to design, develop and commercialize stereopure
nucleic acid therapeutics that precisely target the underlying cause of
rare and other serious genetically defined diseases. Given the
versatility of our chemistry platform, WAVE’s deep, diverse pipeline
spans multiple modalities including antisense, exon-skipping, and
single-stranded RNAi. For more information, please visit www.wavelifesciences.com and
follow us on Twitter at @WAVELifeSci
and LinkedIn.